On Invalid Date, Trinity Biotech (NASDAQ: TRIB) reported Q1 2023 earnings per share (EPS) of N/A, up N/A year over year. Total Trinity Biotech earnings for the quarter were -$5.81 million. In the same quarter last year, Trinity Biotech's earnings per share (EPS) was N/A.
On Invalid Date, Trinity Biotech (NASDAQ: TRIB) reported Q1 2023 revenue of $14.83 million up 5.4% year over year. In the same quarter last year, Trinity Biotech's revenue was $15.68 million.
What was TRIB's revenue growth in the past year?
As of Q3 2023, Trinity Biotech's revenue has grown -14.71% year over year. This is 16.58 percentage points lower than the US Diagnostics & Research industry revenue growth rate of 1.87%. Trinity Biotech's revenue in the past year totalled $70.83 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.